South Korean Pharmaceuticals & Biotech Undervalued based on future growth

Results

0 new

Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)

3 companies

Hugel

Market Cap: ₩2.6t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩238,500.00

11.4%

-13.6%

Dong-A Socio Holdings

Market Cap: ₩691.8b

Engages in the pharmaceutical business in South Korea.

A000640

₩107,500.00

1.7%

-4.5%

Chong Kun Dang Holdings

Market Cap: ₩230.6b

Manufactures and distributes pharmaceutical products in South Korea and internationally.

A001630

₩48,450.00

7.5%

-4.6%